CompletedPhase 4

Prolonged Protection From Bone Disease in Multiple Myeloma

Denmark158 participantsStarted 2015-01

Plain-language summary

Main hypothesis: Patients who continue zoledronic acid after year 2 have longer time until progression in bone disease compared to patients who stop treatment after two years? Secondary hypothesis: Serum will bone markers increase prior to progression in bone disease in the individual patient? Secondary hypothesis: Low-dose CT will detect more cases of osteolytic bone disease in Multiple Myeloma compared to conventional radiography

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Symptomatic Multiple Myeloma regardless of bone disease status * Signed Informed Consent * Age ≥ 18 years * Remaining life expectancy ≥ 2 years * Any concurrently anti-myeloma treatment are allowed Exclusion Criteria: * Previous treatment with bisphosphonate within the last 6 months * Severely reduced renal function (creatinine clearance \<30 mL/min despite fluid replacement) * Known concurrent malignancy, excluding skin cancer * Known hypersensitivity to zoledronic acid * Pregnant or lactating women * Women of childbearing potential or men engaging in sexual activity with a woman of childbearing potential who refuse to use contraception

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

time to first skeletal related event after randomisations at year two

Timeframe: From year two to year four

Trial details

NCT IDNCT02286830

SponsorThomas Lund

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-16

View on ClinicalTrials.gov More Multiple Myeloma trials